ArticlebioRxiv : the preprint server for biology2025
VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials.
Abstract readPreprint
In one paragraph
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors.
Carolyn WilliamsonDivision of Medical Virology, Institute of Infectious Disease and Molecular Medicine and Wellcome CIDRI-Africa Centre, Faculty of Health Sciences, University of Cape Town. Cape Town, South Africa.
Lyle CurryDivision of Medical Virology, Institute of Infectious Disease and Molecular Medicine and Wellcome CIDRI-Africa Centre, Faculty of Health Sciences, University of Cape Town. Cape Town, South Africa.
Nonhlanhla N MkhizeSA MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Elena E GiorgiVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Craig A MagaretVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Bronwen E LambsonSA MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Sinethemba Bhebhe HonsSA MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Haajira KaldineSA MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Thandeka Moyo-GweteSA MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Morgane RollandUS Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Raabya RossenkhanVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Nina Marie G GarciaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0003-0039-4073
Chivonne MoodleyDivision of Medical Virology, Institute of Infectious Disease and Molecular Medicine and Wellcome CIDRI-Africa Centre, Faculty of Health Sciences, University of Cape Town. Cape Town, South Africa.
Anna YsselDivision of Medical Virology, Institute of Infectious Disease and Molecular Medicine and Wellcome CIDRI-Africa Centre, Faculty of Health Sciences, University of Cape Town. Cape Town, South Africa.
Yunda HuangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Alaine A MarsdenSA MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Daniel B ReevesVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Bryan T MayerVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Roger E BumgarnerDepartment of Microbiology, University of Washington, Seattle, WA, USA.
Nicolas BeaumeDivision of Medical Virology, Institute of Infectious Disease and Molecular Medicine and Wellcome CIDRI-Africa Centre, Faculty of Health Sciences, University of Cape Town. Cape Town, South Africa.
Dylan H WestfallDepartment of Microbiology, University of Washington, Seattle, WA, USA.
Michal JuraskaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Allan C DeCampVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Hugh MurrellDivision of Medical Virology, Institute of Infectious Disease and Molecular Medicine and Wellcome CIDRI-Africa Centre, Faculty of Health Sciences, University of Cape Town. Cape Town, South Africa.
Hongjun BaiUS Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Wenjie DengDepartment of Microbiology, University of Washington, Seattle, WA, USA.
Alec P PankowDepartment of Microbiology, University of Washington, Seattle, WA, USA.
Tanmoy BhattacharyaLos Alamos National Laboratory, Los Alamos, NM, USA.
Talita YorkDivision of Medical Virology, Institute of Infectious Disease and Molecular Medicine and Wellcome CIDRI-Africa Centre, Faculty of Health Sciences, University of Cape Town. Cape Town, South Africa.
Nonkululeko NdabambiDivision of Medical Virology, Institute of Infectious Disease and Molecular Medicine and Wellcome CIDRI-Africa Centre, Faculty of Health Sciences, University of Cape Town. Cape Town, South Africa.
Lennie ChenDepartment of Microbiology, University of Washington, Seattle, WA, USA.
Hong ZhaoDepartment of Microbiology, University of Washington, Seattle, WA, USA.
Asanda Gwashu-NyangiriDivision of Medical Virology, Institute of Infectious Disease and Molecular Medicine and Wellcome CIDRI-Africa Centre, Faculty of Health Sciences, University of Cape Town. Cape Town, South Africa.
Ruwayhida ThebusDivision of Medical Virology, Institute of Infectious Disease and Molecular Medicine and Wellcome CIDRI-Africa Centre, Faculty of Health Sciences, University of Cape Town. Cape Town, South Africa.
Paula CohenDivision of Medical Virology, Institute of Infectious Disease and Molecular Medicine and Wellcome CIDRI-Africa Centre, Faculty of Health Sciences, University of Cape Town. Cape Town, South Africa.
Ben MurrellDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institute, Sweden.
Shelly KarunaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
John HuralVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Nyaradzo MgodiUniversity of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Harare, Zimbabwe.
Srilatha EdupugantiDepartment of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.
Lynn MorrisSA MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
David MontefioriDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Myron S CohenDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Lawrence CoreyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Paul T EdlefsenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Peter B GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Penny L MooreCentre for the AIDS Programme of Research in South Africa, University of Kwa-Zulu Natal, Durban, South Africa.
James I MullinsDepartment of Microbiology, University of Washington, Seattle, WA, USA.
Funding
LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6MLOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5MLC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6MSDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9MSDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9MLC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2MHIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapyR01AI157854 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI KURITZKES, DANIEL R., TSIBRIS, ATHE M. · 2021 to 2025
$4.0MPhylodynamic mechanisms of HIV reservoir seeding and maintenanceR01AI186721 · NIAID · FRED HUTCHINSON CANCER CENTER · PI Daniel Reeves · 2024 to 2026
$2.6MAntigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan AfricaR01AI152115 · NIAID · UNIVERSITY OF CAPE TOWN · PI GILBERT, PETER B., WILLIAMSON, CAROLYN · 2020 to 2024
$1.7MSimulating persistence and elimination of the HIV reservoirK25AI155224 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI REEVES, DANIEL · 2020 to 2024
$581kGates Foundation INV-016189NIAID NIH HHS K25 AI155224NIAID NIH HHS R01 AI152115NIAID NIH HHS R01 AI157854NIAID NIH HHS R01 AI186721NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI068635
Abstract
Broadly neutralizing antibodies (bnAbs) show promise in HIV prevention, yet viral escape remains a challenge. In the Antibody Mediated Prevention (AMP) trials, the CD4 binding site (CD4bs) bNAb VRC01 blocked acquisition by VRC01-sensitive strains. However, its influence on viral evolution post-acquisition is not fully understood. Here we analyzed >12,000 HIV env sequences from 47 participants from the AMP trials, identifying VRC01-mediated
Indexed as
antibody mediated preventionbroadly neutralizing antibodies (bnAbs)HIVHIV VRC01 escape mutationsVRC01 resistance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.